https://www.selleckchem.com/products/YM155.html
The study was designed as a phase III, randomized, multicenter, double-blind, investigator-initiated clinical study with a 12-month follow-up (ClinicalTrials.gov Identifier NCT04718025; EudraCT number 2020-005130-15).Starting in the mid-eighties, the AO (from the German "Arbeitsgemeinschaft für Osteosynthesefragen" Research Institute (ARI), Davos, Switzerland together with the commercial partners of the AO Foundation embarked on a decade-long project to design, develop, test in experimental animals and human clinical trials as well as br
Like
Comment
Share
